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Abstract
Background: Sydenham’s chorea (SC), the neurologic manifestation of rheumatic fever, remains the most prevalent form of chorea in children. Suggested
treatments of chorea in SC include prophylactic penicillin, symptomatic (antipsychotic and anticonvulsant) medications, and immunomodulatory therapy (steroids,
intravenous immunoglobulin (IVIG), and plasma exchange). In this manuscript, we undertook a systematic review of the published literature to examine the data
supporting these therapeutic recommendations.
Methods: A search of PubMed, Embase, Psychinfo, and clinicaltrials.gov was conducted for publications pertaining to the treatment of SC/rheumatic chorea
from 1956 to 2016.
Results: Penicillin prophylaxis appears to reduce the likelihood of further cardiac complications and the recurrence rate of chorea. Data on symptomatic therapy
for chorea are limited to individual case reports or series and rare comparison studies. The efficacy of steroid use is supported by a single placebo-controlled study
and several case series. Information on other immunomodulatory therapies such as IVIG and plasmapheresis are limited to a small number of reports and a single
comparison study.
Discussion: Treatment decisions in SC are currently based on the treating physician’s clinical experience, the desire to avoid side effects, and the existence of only
limited scientific evidence. Based on a review of the available literature, chorea often improves with symptomatic therapy and immunotherapy tends to be reserved
for those who fail to respond. Steroids are beneficial; however, data using IVIG and plasmapheresis are very limited. Larger, well-controlled studies, using
standardized assessment scales, are required if therapeutic decisions for SC are to be based on meaningful information.
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Introduction
‘‘The formulation of the problem is often more essential than its
solution, which may be merely a matter of mathematical or
experimental skill’’ Albert Einstein
Sydenham’s chorea (SC), one of the major criteria for the diagnosis
of rheumatic fever, is the most common form of autoimmune chorea.
The typical age of onset of SC is 5–15 years and females are more
affected than males. Chorea usually develops 4–8 weeks after a group
A beta-hemolytic streptococcal (GABHS) pharyngitis; this is later than
other manifestations of rheumatic fever, such as carditis or arthritis,
which usually develop 2–3 weeks after infection. Classically, chorea in
SC is generalized; however, hemi-chorea occurs in about one-quarter
of patients. Although symptoms can be mild, even in these instances
difficulty with grooming, feeding, and handwriting can interfere with
daily activities in school or work. Other neurologic symptoms in SC
can include motor impersistence, hypometric saccades, reduced muscle
tone, tics, clumsiness, dysarthria, and weakness. In rare instances the
associated hypotonia can be so profound as to be completely disabling,
a variant known as chorea paralytica or chorea mollis. Neuropsychiatric
symptoms, including obsessive compulsive behaviors, personality chan-
ges, emotional lability, distractibility, irritability, anxiety, age-regressed
behaviors, and anorexia, are common and frequently predate the
appearance of chorea.1 After improvement of their motor symptoms,
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many patients with SC continue to have a high rate of anxiety and
depression2 as well as difficulty with cognitive tasks requiring attention
and processing speed.3 Cardiac involvement, especially affecting the
mitral valve, occurs in about two-thirds and arthritis in about one-third
of SC patients. Patients initially presenting with only chorea but no other
symptoms of rheumatic fever may develop cardiac involvement during
a recurrence.4 Classically, SC is expected to resolve in 1–6 months.
A retrospective study of 90 patients showed complete remission of motor
symptoms in 85% by 6 months, and an additional 5% had complete
remission by 1 year.5 In contrast, other groups have reported a greater
persistence of motor symptoms in their populations. One prospective
study of 32 patients with SC, followed for more than 2.5 years, found
that symptoms persisted for 2 years or more in 50% of their cases.6
No predictive demographic features for a prolonged course were identi-
fied. Additionally, recurrences of chorea are not uncommon, occurring
in 15–40% of patients,5,7 Identified triggers for relapses have included
poor prophylactic penicillin adherence,5 the use of oral contraceptive
agents, and pregnancy.8 Investigative laboratory studies assist in elimi-
nating alternative causes of chorea, but do not confirm the diagnosis.
Elevated antistreptococcal titers are present in about 15–30% and
imaging is usually normal, except for possible acute phase enlargement
of the basal ganglia and increased T2 intensity in rare cases.9 Persistent
magnetic resonance imaging changes have been reported, particularly in
patients with recurrent episodes of chorea.10
Pathophysiologically, acute SC is believed to be associated with
antibodies against GABHS that cross-react, through the process of
molecular mimicry, with either neuronal extracellular surface and/or
intracellular (cytoplasmic or cytoskeletal) antigens. Initial evidence for
an autoimmune disorder was based on the presence of immunoglo-
bulin G reactivity to neuronal cytoplasm in human caudate and sub-
thalamic nuclei that correlated with the severity and duration of
symptoms.11 Subsequent studies have shown that both acute sera and
monoclonal (mAB 24.3.11) antibodies in SC patients activate Ca2+/
calmodulin-dependent protein kinase (CaMKinase) II activity in a
human neuronal cell line (SKNSH).12,13 This activation is believed to
cause clinical symptoms by altering neuronal cell signal transduction,
especially involving dopamine.14 Serum antibodies have also been iden-
tified in enzyme-linked immunosorbent assay titers against dopamine
D1 and D2 receptors;15–17 attempts to confirm binding to D1 and D2
receptors in their conformational states in human cell lines have been
mixed.16,18 These results provide theoretical support for trials of immu-
nomodulatory therapies in SC.
Proposed treatments of chorea in SC currently include acute and
prophylactic penicillin therapy, symptomatic medications, and possibly
immunomodulatory therapy. The list of suggested symptomatic thera-
pies is broad and contains the off-label use of anticonvulsants (valproate,
carbamazepine) and neuroleptics (pimozide, haloperidol, risperidone,
olanzapine). Once the patient becomes symptom free for at least
1 month, it is suggested that medications be gradually tapered. In the
case of uncontrolled or persisting chorea, recognizing the proposed
autoimmune etiology for SC, reports have recommended the use of
steroids, intravenous immunoglobulin (IVIG) or plasma exchange. The
goal of this report was to systematically review the evidence for the use
of antibiotics, symptomatic, and immunomodulatory therapy for the
treatment of chorea in SC. Therapies for neuropsychiatric symptoms
commonly seen in individuals with SC are not covered in this review.
Methods
‘‘Science is a method to keep yourself from kidding yourself’’
Edwin Land
Separate online searches were conducted using PubMed, Embase,
Psychinfo, and clinicaltrials.gov in March 2017 for the years 1956 to
2016, The collection of references was restricted to human trials using
the keywords ‘‘Sydenham’s’’ or ‘‘Sydenham’’ or ‘‘rheumatic chorea’’ and
‘‘treatment’’ or ‘‘antipsychotic’’, ‘‘antipsychotics, ‘‘ antiepileptic,’’ ‘‘anti-
epileptics,’’ ‘‘immunosuppressive,’’ ‘‘AED’’ (antiepileptic medication),
‘‘AEDs,’’ ‘‘haloperidol,’’ ‘‘pimozide,’’ ‘‘risperidone,’’ ‘‘olanzapine,’’ ‘‘car-
bamazepine,’’ ‘‘valproic acid,’’ ‘‘valproate,’’ ‘‘steroid,’’ ‘‘steroids,’’ ‘‘meth-
ylprednisolone,’’ ‘‘prednisone,’’ ‘‘corticosteroid,’’ ‘‘corticosteroids,’’
‘‘immunoglobulin,’’ ‘‘IVIG,’’ ‘‘plasmapheresis,’’ or ‘‘plex’’ but
not ‘‘Huntington.’’ Manuscripts primarily focused on other diseases,
without abstracts, or written in a language other than English were
excluded. The same strategy was used for the collection of references
from each database, i.e., PubMed (2,280); Embase (355), and
Psychinfo (183). Clinicaltrials.gov was also searched, but no additional
studies of interest were identified. From a total of 2,780 identified
references (including duplicates), 71 articles were selected for further
review, 44 being directly related to treatment.
Results
‘‘Not everything that can be counted counts, and not everything
that counts can be counted’’ Albert Einstein
Quality of assessments and use of rating scales. The methodologies
used to assess clinical symptoms and outcomes in the reviewed refe-
rences varied widely. In 30 studies, the authors merely reported
qualitative improvement,10,19–46 and only one included an unbiased
observer.23 One report used the Modified Abnormal Involuntary
Movement Scale, which is intended for tardive dyskinesia.47 Five
reports used unverified scales that were designed based on prior
literature;48–52 and only four used the Universidade Federal de Minas
Gerais Sydenham’s Chorea Rating Scale (USCRS).53–56 The USCRS
was published in 2005 and subsequently recommended as the optimal
scale for the assessment of clinical symptoms in SC.57
Another significant deficit in multiple reports is the failure to pro-
vide sufficient information on the time course of improvement.
For example, reports varied on whether they provided the time
to improvement of symptoms (10 out of 44),19,25,27,30,35–38,42,55 the
time to full remission of symptoms (two out of 44),21,28 or both (13 out
of 44).20,22–24,26,32,33,35,41,44–46,52,53 Nine out of 38 studies reviewed
improvement in a chorea score at fixed weekly, monthly, or yearly
intervals, rather than reporting the time to an observed improvement
or recovery.29,40,47–51,54,56 Twenty-eight out of 44 reported the total
length of time treatment was provided.20,22–30,32–36,38,44–46,48–56
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Antibiotic treatment and prophylaxis. Despite the fact that patients
commonly do not have an active infection at the time of the
appearance of chorea, most published treatment recommendations
include a 10-day course of oral penicillin or a single intramuscular
(IM) dose of penicillin at the time of SC diagnosis.50 Sulfa drugs
are commonly used for those individuals with a penicillin allergy.
In the reviewed literature, only four papers (11 patients) reported
throat culture results at the time of diagnosis (five positive, six
negative).28,32,34,45,52
Secondary prophylaxis to prevent future streptococcal infections
is advocated. More specifically, the World Health Organization
recommends 1.2 million units of penicillin G administered IM every
21 days. The duration of treatment is dependent on the severity of
cardiac involvement. Patients with no carditis may stop prophylaxis
after 5 years or age 18 (whichever is longer), those with mild carditis
should continue for 10 years or age 21, and those with moderate
to severe carditis should receive lifelong prophylaxis.58 However,
this literature review identified significant diversity of antibiotic
treatment and/or reporting. Twenty-one studies failed to com-
ment on whether primary or secondary penicillin treatment was
utilized19–21,23,25,26,29,31,33–36,39,45,46,48,51,54–56 and 10 reports did
not comment on the length of treatment or method of deliv-
ery.22,24,28,35,40,42–44,51,53 One study reported primary but not
secondary penicillin treatment.47 Studies that reported penicillin use
varied in terms of its method of administration; either oral or IM
primary penicillin therapy preceding IM prophylaxis,10,32,37,49,50 or in
the substitution of amoxicillin followed by prophylaxis with feneticillin.
One report specifically noted that although secondary prophylaxis with
penicillin was recommended to all patients, it was not received in
most.30 One patient reportedly received no antibiotics, although this
was not intentional.27 One patient underwent tonsillectomy for repea-
ted infections, but the use of antibiotic treatment was not described.41
Secondary antibiotic prophylaxis has been shown to reduce the risk
of new cardiac lesions associated with recurrent rheumatic fever. The
effect of prophylaxis on the recurrence of chorea, however, is less clear.
In a prospective study of 31 SC patients in Chile, all undergoing
monthly prophylaxis with benzathine penicillin G, 17 separate recur-
rences of ‘‘pure’’ chorea were detected in 10 individuals (six girls), with
data collection being adequate in 16 out of 17 occurrences.59 In four
out of 16, the recurrence was associated with either high stationary
antistreptococcal antibody levels or a sudden rise in levels followed by
a decline prior to the exacerbation. In eight out of 16 recurrences,
there were modest elevations in levels (antistreptolysin O (ASO)
50–133 Todd units, median 100; antiDNaseB 170–680, median 170).
In four out of 16 there was no evidence of a recent streptococcal
infection or elevated titers. In a similar study performed in Jerusalem,
10 out of 19 SC patients (seven females) developed a total of 11
recurrences of chorea.7 Only six out of 11 recurrences were associated
with either poor penicillin adherence or an increase in ASO titers.
These reappearances of chorea were not predictable by either prior
rheumatic fever activity or cardiac findings. In contrast, a retrospective
study of 90 SC patients in Turkey showed that those adherent to their
secondary prophylaxis regimen had a significantly lower recurrence
rate (nine out of 82 patients) than those who had only irregular
prophylaxis (five out of eight patients).5 In another study, penicillin
adherence rates in all patients with SC were 71% (61 out of 85) and
53% (nine out of 17) in patients with recurrent chorea and adequate
follow up information.60 Hence, available data suggest that prophy-
laxis likely reduces the rate of recurrence, but it does not completely
prevent it.
Symptomatic treatment
Dopamine antagonists. Several dopamine antagonists have been utilized
in worldwide studies to treat chorea, the most common being the
neuroleptics haloperidol and pimozide (Table 1). In 1972 haloperidol
(4–5 mg daily, divided twice a day or three time a day) was successfully
used in two patients that had previously failed phenothiazine,
diazepam, sedation, and/or amantadine.39 Four additional patients
responded within several days to haloperidol 1–3 mg.33 In a retro-
spective analysis of 100 SC patients, haloperidol was successfully used
in 82 out of 87 and was ineffective in five; the latter were subsequently
treated with prednisone.31 Of the remaining 13 subjects, one was
successfully treated with chlorpromazine and treatment could not be
determined by case review in 12.
Pimozide (2 mg twice a day) was reported successful in a total of five
patients.35,37 A retrospective review of patients in Turkey compared
results between haloperidol and pimozide and reported that halo-
peridol had a significantly faster average onset of symptomatic impro-
vement (haloperidol 14 days vs. pimozide 29 days); average time to
becoming symptom free (haloperidol 42 days vs. pimozide 109 days);
lower treatment failure rate (haloperidol ineffective in three vs.
pimozide in five) but a greater number of drug withdrawals because of
side effects (haloperidol 3 vs. pimozide 1).20 This study is, however,
difficult to interpret because the authors provided the initial treatment
choice in 65 patients but were only able to gather adequate data in
29 patients, and failed to identify the specific treatment within this
group. Side effects leading to haloperidol withdrawal included dys-
tonia, parkinsonism, sleepiness, and cognitive issues and for pimozide,
sleepiness, headache, dry mouth, and numbness. Tardive dyskinesia
was not reported in any reviewed study.
Haloperidol and pimozide are described as successful agents in
some case series focusing on other aspects of SC and as a failed
primary therapy in published reports describing alternative agents.
Data from these studies were incorporated into our total number,
recognizing that negative case reports usually go unpublished and
the deficiency of placebo-controlled trials. Thus, taking all evalua-
ted studies into consideration, the results are as follows: for haloperi-
dol, 133 out of 159 patients were successfully treated solely with
this medication;10,20,25,31,33–35,39,40,42,44 treatment was ineffective in
119,10,19,20,25,31,35,48,52,55 and was discontinued because of side effects
in seven.10,19,20 Of note, these numbers do not include 20 patients
treated with either haloperidol or haloperidol plus IVIG (discussed
later),50 since it was difficult to incorporate the results of this dual
therapy trial into a discussion of haloperidol efficacy. Similarly, the
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total excluded data from the previously discussed Turkish study which
failed to provide the final number of patients successfully treated with
haloperidol.20 Pimozide was successfully used in at least six out of
17 patients,10,35,37 plus an unclear number of additional patients in one
study discussed above.20 It was ineffective in 10,10,20,48 and discon-
tinued because of side effects in one.20
Chlorpromazine using an ill-defined dose was successful in 10 out of
12 patients.20,35,42,44 In one study, five out of 91 patients developed
Parkinsonism; however, no additional information was available about
the effectiveness of chlorpromazine in the other 86 subjects.61 Olan-
zapine (5–10 mg/day) was successfully used in six patients with
improvement seen in 2 days and remission of symptoms in 2–
3 weeks.46 Similar agents, such as risperidone (dose 1–2 mg twice a day),
have been recommended by some authors62 in an effort to decrease
the likelihood of extrapyramidal side effects. A lack of reports, how-
ever, limits the ability to assess their efficacy compared with other
agents. Risperidone is mentioned as a failed treatment in a study
focusing on plasmapheresis (discussed below).29 In addition to antipsy-
chotic medications, other agents that act on the dopaminergic system
have been utilized to treat chorea in SC. Tetrabenazine, which inhibits
the uptake of monoamines and causes the depletion of monoamine
storage,63 is approved for the treatment of chorea in Huntington’s
disease. A 1977 case report suggested that tetrabenazine administered
to two patients with SC (25 twice a day or three times a day), is an
effective chorea therapy in SC.38 Symptomatic improvement was
observed in 24 hours and resolution of symptoms occurred in 2 weeks.
Other reports describe tetrabenazine failure in a single patient37 and
side effects including quadriparesis and dysarthria that resolved with its
withdrawal.40
It has been suggested that patients with SC may be particularly
vulnerable to extrapyramidal side effects. For example, several studies
noted above described treatment-limiting side effects with the use of
haloperidol.19,20,31 Support for increased neuroleptic side-effect sus-
ceptibility in SC also comes from a comparison of five out of 91 cases
with SC who developed significant extrapyramidal side effects on
chlorpromazine as compared to 10 age-matched patients with Tourette’s
syndrome (TS) receiving equivalent medication doses.61 Unfortunately,
this protocol controlled for age but not gender, and four of the five
patients in the SC group were female, compared with only two out of
10 TS controls. Thus, it is unclear whether this sensitivity is unique to
SC or reflects a gender difference. An additional study reported that
19 out of 32 SC patients had motor symptom side effects secondary to
the use of other medications that affect the dopaminergic system,
including decongestants, stimulants, and antiemetics, but no control
group was provided.64
Antiepileptic medications. Given the reported side effects of dopamine
antagonists, alternative symptomatic treatments have been sought.
Two case reports found that valproic acid (20 mg/kg/day or 250 mg
twice a day) was effective in two SC patients who had previously
failed either haloperidol or diazepam.19,22 Ten patients responded to
valproic acid (20 mg/kg/day) as a secondary treatment, although the
specific agents trialed before valproic acid are not specified.23 A slightly
higher dose of 300 mg twice a day was used successfully in a case of
chorea paralytica.41 An additional three case series containing a total
of 26 patients reported successful treatment with valproic acid (20–
25 mg/kg or 600–800 mg/day) as initial therapy in 24 out of
26 patients.30,36,45 For all studies reviewed in which valproic acid
was prescribed, it was reported to be effective in a total of 64 out
of 78 patients,10,19,21–23,25,26,30,35,36,41,42,45,46 and ineffective in 14
patients.10,29,34,36,48,52,53 There are no reports of side effects including
sedation, vertigo, or liver failure. One patient had severe hypotonia,
although this did not recur when the drug was reintroduced.36 Where
reported, symptomatic response occurred between 12 hours and 10 days,
and complete remission of symptoms occurred in 1–4 weeks, except
in the case of chorea paralytica, where remission was reported within
14 months. Of note, time to response was not reported in this patient.
Carbamazepine is also reported to be effective. In one case report
two patients with SC treated with carbamazepine (15–20 mg/kg) had
improvement 1 week after therapy initiation, and complete remission
in 1–2 months.44 Another report evaluated nine patients treated with
carbamazepine (4–10 mg/kg) prospectively as first line therapy.24
Chorea improved in 2–14 days and complete remission occurred in
2–12 weeks. A pruritic rash was the only side effect reported and did
not limit treatment. A small comparison study randomized 18 SC
patients to treatment with either carbamazepine, valproic acid, or
haloperidol.25 A good clinical response was noted in six out of six
patients treated with valproic acid (20 mg/kg/day); five out of six
treated with carbamazepine (15–20 mg/kg/day); and in three out of
six treated with haloperidol (3 mg/kg/day). Of note, no statistical
analysis of efficacy was performed and there was no placebo control
group. The authors did, however, describe a good clinical response to
valproate in the four patients who failed initial treatment with either
haloperidol or carbamazepine. A third study showed no significant
difference in time to symptomatic improvement, duration of improve-
ment, or side effects between carbamazepine (15 mg/kg; n517) and
valproic acid (20 mg/kg; n57) groups.26 In the total reviewed
literature, carbamazepine was reported to be effective in 33 out of
34 patients24–26,31 and ineffective in one.25
In terms of other antiepileptic medications, levetiracetam has been
mentioned as an attractive option because of its favorable side effect
profile. To date, however, despite its prescription in other choreiform
disorders, there is only a single case report of its successful use in SC.55
No other reports, positive or negative, were identified specifically for
levetiracetam. Phenobarbital is rarely used today because of sedation
and other side effects, but it has been reported to be effective in at least
13 SC cases.42 Similarly diazepam is reported as effective in at least
three out of four patients in older reports, but rarely in reports after
2000.35,42
Immunomodulatory treatment
Steroids. Given that Sydenham’s chorea is proposed to be an
autoimmune disorder, immunomodulatory treatments have also been
utilized (Table 2); steroids being the most frequently reported therapy.
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Prednisone (1 mg/kg orally for 5 days with gradual taper) was
successfully used to treat chorea in five patients who had previously
failed therapy with haloperidol.31 Initial therapy with prednisone
(2 mg/kg for 3 weeks with a 3 week taper) was successful in five
patients, with a clinical response in 24–48 hours, and total remission in
7–12 days.32 A double-blind randomized control trial compared
22 patients treated with oral prednisone (2 mg/kg/day for 4 weeks
with a 25-day taper) with 15 patients treated with placebo.49 Clinical
response was noted in 1 week in the prednisone group and 2 weeks in
the placebo group. Complete remission was achieved by 54 days in the
prednisone group and 120 days in the placebo group. The authors
concluded that steroids significantly decreased chorea intensity and the
time to remission, although relapse rates were the same in both groups.
As noted by others,62 however, significant limitations of this study
include the use of a non-validated chorea rating scale and failure to
control for the simultaneous use of haloperidol in both the prednisone
(n54) and placebo (n57) groups. Further, statistically significant
visibly detectable side effects, including weight gain (2.3 kg in the
prednisone group versus 0.5 kg in placebo group at 8 weeks), and a
cushingoid appearance in the prednisone group, may have compro-
mised observer blinding. Other steroid treatment studies include eight
patients who received corticotrophin (30–40 mg intravenously for
3–9 days), followed by prednisone (30–75 mg for 5–10 days), and a
90-day taper.27 A total of 20 patients in three additional studies were
treated with intravenous methylprednisolone (25 mg/kg/day or 1 g/day
in adults) for 5 days followed by either a prednisone taper (1 mg/kg/day
oral prednisone; n510)48,56 or deflacort (0.9 mg/kg/day; n510).53 Of
note, 14 of these patients had chorea paralytica.53,56 In these three
studies, steroids represented either the initial treatment (n55) or treat-
ment following a failure to respond to pimozide, haloperidol, valproic
acid, or chlorpromazine (n515). Clinical response was noted in 2–5 days,
after the initiation of steroid therapy. Reviewing all available literature,
combining both IV and oral steroid treatment, and recognizing variability
in agents, dosing, and administration route, steroid therapy was successful
in 76 out of 77 patients.10,27,29,31,32,36,43,48,49,51,53,56 Only one failure of
steroid treatment was reported.29 Two patients overall developed
Cushing’s syndrome48 and a transient weight gain with moon facies
was reported in an additional patient.56 In two other studies (total
n528),49,51 a weight gain and moon face was reported, but the
number of individuals with these side effects was not provided.
IVIG. Case reports utilizing IVIG include a total of four patients who
improved following the receipt of IVIG (a total of 2 gm/kg) over
5 days.28,52,54 One subject had failed valproic acid and haloperidol
prior to treatment with IVIG, whereas the others were treated with
IVIG as a primary therapy. Therapeutic improvement was reported in
4 days in one out of four patients; improvement time for the others was
not clearly specified. A previously mentioned small comparison study
evaluated 10 children treated with haloperidol alone versus 10 child-
ren with haloperidol plus IVIG (total of 2 gm/kg) administered over
2 days.50 Based on ratings by a blinded observer, there was a statistically
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6 months of treatment and a reduced duration of haloperidol treatment
compared with those receiving only haloperidol. Concerns for this study
include lack of placebo control arm, use of a non-validated rating scale,
and failure of the blinded observer to perform the initial evaluation at
the beginning of the protocol. In a follow-up of these patients, it has been
suggested that there might be a difference in executive function at 1, 3,
and 6 months between those subjects treated with IVIG + haloperidol
compared with haloperidol alone.65 Statistical analyses included a com-
parison to a ‘‘healthy’’ control group, rather than a simple comparison of
the original cohorts. In summary 18 out of 18 patients appeared to
respond to IVIG, including an additional comparison study of IVIG,
plasmapheresis and steroids (discussed below). No reports of clear IVIG
failure have been published nor have publications described side effects.
Plasmapheresis. In a single individual case report, five rounds of
plasmapheresis were successfully used to treat a patient with SC who
had previously failed valproic acid, risperidone, and IV steroids/per os
(PO) taper.29 A comparison study evaluating results in patients who
received IVIG (n54), plasmapheresis (n58), or oral prednisone (n56),
showed no significant differences between groups.51 The authors did,
however, note that the chorea severity score was variably reduced in
the different treatment groups at 1 month: IVIG 72%, plasmapheresis
50%; oral prednisone 29%. Based on this finding it was suggested that
IVIG therapy might lead to a quicker recovery. Limitations of this
study include the small number of subjects, the lack of a placebo arm,
use of a non-validated rating scale, and the fact that study participants
were also receiving a variety of symptomatic treatments (valproic acid,
haloperidol, benzodiazapines). No side effects were reported in pub-
lished studies.
Other treatments. A single case report suggested improvement of
symptoms in four patients with SC because of the administration of
vitamin E (50 IU) administered daily for 2 weeks.47 No other literature
was identified evaluating this treatment.
Discussion
‘‘A point of view can be a dangerous luxury substituted for insight
and understanding’’ Marshall McLuhan
The goal of this review was to critically analyze the available
literature on the treatment of chorea in individuals with SC. To
achieve this goal, available case reports, case series, and treatment
trials were reviewed. Although it was previously recognized that data
were limited, it was enlightening to recognize the significant deficit of
valid scientific evidence for all reported therapies. Most available
therapeutic information exists in case reports, case series, or small
comparative series, and only a single study was placebo controlled.
Further complicating therapeutic decision-making is the fact that the
sole placebo-controlled study reported improvement of chorea after
2 weeks of placebo treatment.49 Hence, based on this information,
it becomes more difficult to assert that the reported success of a thera-
peutic agent represents its beneficial action or merely a therapeutic
tincture of time. In addition, studies vary on when and how clinical
assessments were performed, whether treatment was primary or
secondary, and how long symptoms had been present before treat-
ment was initiated. While the relative rarity of SC and its natural
clinical variation is recognized, larger, better-controlled studies, using
a uniform standard and a validated rating scale, are required before
definitive therapeutic recommendations can be presented. Future
studies utilizing the USCRS to assess the response to therapy are
required and not just highly desirable. Placebo-controlled trials would
be ideal, but are difficult to justify.
All symptomatic treatment of chorea in SC is based on the off-label
use of medications in small case series or comparison studies, none of
which are placebo controlled. Given that chorea typically resolves
spontaneously over time, in very mild cases, pharmacotherapy may be
unnecessary. This non-therapeutic approach was successfully utilized
in 12 of 65 patients in one case series.20 Clearly, in patients with more
significant symptoms, therapy is recommended. Evidence is insuffi-
cient, however, to strongly recommend one drug over another.
Pathophysiologically, chorea has been associated with neurotrans-
mitter alterations within basal ganglia circuits, either excessive dopa-
minergic transmission, or a lack of gamma-aminobutyric acid (GABA)
ergic (inhibitory) or acetylcholinergic activity.66 As described, several
antidopaminergic agents have been reported to be effective in treat-
ing chorea. The available literature supports a beneficial response to
haloperidol; however, it is the neuroleptic most reported to cause
unacceptable side effects. On the basis of the available information,
pimozide, which has fewer side effects, may be less effective. Chlor-
promazine may be effective, but detailed information on dosing and
efficacy is lacking. Atypical antipsychotics, such as risperidone and
olanzapine, are favored by some authors, but again there is little
evidence supporting their use.
Several AEDs alter GABAergic neurotransmission making them
potential candidates for the treatment of chorea. Medications such as
valproic acid and carbamazepine, are attractive choices based on their
low side effect profile and preliminary suggestive data that they may be
as effective as haloperidol.
Immunomodulatory therapies for the treatment of chorea in SC
remain controversial primarily due to their invasive nature and
potential side effects. Recognizing that some studies suggest that
recurrent episodes of SC may not be immune mediated,7,59 future
studies of immunomodulatory therapies should attempt to correlate
outcomes with measurements of proposed biomarkers. Accumulating
evidence does support a beneficial effect of steroids. Prior recommen-
dations in the literature have suggested reserving this approach
for patients with severe chorea including chorea paralytica, those
unresponsive to symptomatic therapies, or individuals with unaccep-
table side effects. Steroids have been used as first-choice therapy in
chorea paralytica, although there is also a single case report of
successful treatment using valproic acid. Of note, immunosuppression
with steroids should be utilized with particular caution in areas where
diseases such as tuberculosis are endemic.67 Other immunomodulatory
therapies such as IVIG and plasmapheresis have been tried in a small
number of patients, but remain relatively untested.
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Figure 1. Treatment Recommendations. Our suggested approach to treatment is presented.
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Conclusions
When considering a therapeutic agent for the treatment of chorea
in individuals with SC, the practitioner should consider the severity of
the problem, the requirement for a therapeutic agent, its availability,
cost to the family, extent of supporting evidence, and the therapy’s side
effect profile. Given that the literature does not clearly demonstrate
one treatment being clearly superior, a practitioner’s personal expe-
rience and comfort with a given agent will likely guide their ultimate
therapeutic choices. Based upon our review of the literature, a sug-
gested potential therapeutic pathway for the treatment of chorea in SC
is presented in Figure 1. Based upon the number of successful reports
and their favorable side-effect profiles, we favor the initial use of
valproic acid (20 mg/kg/day) or carbamazepine (15 mg/kg/day). As
they have more significant side effects and there is a lack of evidence
that they are more effective, neuroleptics should be reserved for
patients who fail valproic acid or carbamazepine therapy. We concur
with others that there is evidence to support a role for immunomo-
dulatory therapy. Nevertheless, we believe that it should be reserved
for patients with chorea paralytica or for those with disabling symp-
toms who fail, or cannot tolerate, symptomatic treatment. Of the
immunomodulatory therapies investigated, steroids have the strongest
supporting evidence, but side effects are not uncommon. Oral pred-
nisone (2 mg/kg/day) for 3–4 weeks with prolonged taper and
methylprednisolone (25 mg/kg/day) with a prolonged taper are the
two most commonly utilized regimens. Although there is a theoretical
basis for IVIG and plasmapheresis and it appears to have at least equal
efficacy in a single small comparison study, we hesitate to recommend
these approaches before a trial with steroids. In conclusion, the pre-
paration of this manuscript has enlightened us to the acute need for
well-controlled studies to assist in clarifying the most appropriate
therapy for the treatment of chorea in Sydenham’s chorea.
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